Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Zhenglin Yao"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Cyclin-dependent kinases, CDK4 and CDK6, are essential in regulating the cell cycle, which is disrupted in cancers like isocitrate dehydrogenase wild-type glioblastoma (GBM). Currently marketed CDK4/6 inhibitors, including abemaciclib, have shown pre
Externí odkaz:
https://doaj.org/article/f181ab9d2f944ff7b4efa9fd4861ee7e
Publikováno v:
Neuro-Oncology. 23:vi166-vi166
Glioblastoma multiforme (GBM) is characterized by a high frequency of cyclin-dependent kinase (CDK)4 and CDK6 pathway dysregulation. None of the approved CDK4/6 inhibitors are indicated for GBM. Poor blood–brain barrier (BBB) penetration is a poten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6093e73be9ef14b21a46bad5c3b2f7d3
https://doi.org/10.1093/neuonc/noab196.653
https://doi.org/10.1093/neuonc/noab196.653
Publikováno v:
Journal of Clinical Oncology. 39:e14023-e14023
e14023 Background: Glioblastoma multiforme (GBM) is characterized by a high frequency of cyclin-dependent kinase (CDK)4 and CDK6 pathway dysregulation. CDK4/6 inhibitors palbociclib and abemaciclib are approved for the treatment of breast cancer, but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebb74aca3918d207b98c5588f6d8f265
https://doi.org/10.1200/jco.2021.39.15_suppl.e14023
https://doi.org/10.1200/jco.2021.39.15_suppl.e14023
Autor:
Xiaodong Wang, She Chen, Zhiyuan Zhang, Huayi Wang, Lin Li, Zhenglin Yao, Lei Liu, Yan Ren, Shaoqiang Huang, Bo Yan
Publikováno v:
Chemical communications (Cambridge, England). 53(26)
We report the development of novel Mixed Lineage Kinase Domain-Like protein (MLKL) inhibitors with single nanomolar potency (compound 15 is also named as TC13172). Using the converting biochemistry to chemistry activity-based protein profiling (BTC-A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::219b65235b77cdbd6638c2b6faeeb8d2
https://pubmed.ncbi.nlm.nih.gov/28267172
https://pubmed.ncbi.nlm.nih.gov/28267172
Autor:
Yanjin Zhao, Pengyu Qian, Yanyang Li, Yan Zhou, Wenxiang Hu, Falong Jiang, Zhenglin Yao, Yongzhen Wang, Shuxin Li
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 23:179-182
A series of novel benzamides derivatives was designed and synthesized as HDAC inhibitors. Exploration of the structure–activity relationships resulted in compounds that are potent in vitro. In addition, the best compound 1a exhibited an acceptable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f9f5b33bee552cc571ddcda7ffce93a
https://doi.org/10.1016/j.bmcl.2012.10.114
https://doi.org/10.1016/j.bmcl.2012.10.114
Autor:
Wei Chen, Xianzhao Kuang, Zhenglin Yao, Yanjin Zhao, Shan Yao, Wenxiang Hu, Shanyou Yu, Wenhu Zhan, Shuxin Li, Huijia Wang
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:5279-5282
A series of acrylamide analogues were designed and synthesized from Imatinib and Nilotinib as novel BCR-ABL inhibitors by application of the principle of nonclassical electronic isostere. All new compounds were evaluated for their inhibitory effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab2c2cb9ec4f54792d8cc4e1d6826e3
https://doi.org/10.1016/j.bmcl.2012.06.044
https://doi.org/10.1016/j.bmcl.2012.06.044
Autor:
Falong Jiang, Weiping Huang, Yanyang Li, Shan Yao, Yanjin Zhao, Zhenglin Yao, Shoujun Yuan, Shanyou Yu, Wenhu Zhan, Shuxin Li
Publikováno v:
Bioorganicmedicinal chemistry. 20(14)
A series of novel bis-aryl ureas containing trifluoromethyl imidazolyl group targeting Raf kinase were designed and synthesized based on the lead compound of Sorafenib. All the prepared compounds were evaluated for their in vitro antiproliferative ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31610f35b924476b71958bc1732d9038
https://pubmed.ncbi.nlm.nih.gov/22721924
https://pubmed.ncbi.nlm.nih.gov/22721924